Important: “Obesity Blocker” Trading Action Alert
As I told you yesterday, the FDA Advisory Committee has voted to recommend what we’ve been calling “the obesity blocker.” This morning in pre-market trading, our stock is up by about 20% from its closing price of $1.52 on June 16, 2014. I still believe that it’s still incredibly undervalued. But we're not seeing the huge percentage gain in the stock price that I anticipated when I recommended you buy the stock. Why? I believe it's because the FDA Advisory Committee, despite recommending the “obesity blocker” device, dinged it with a negative vote on its efficacy.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.